Thrivent Financial for Lutherans
SUPN icon

Thrivent Financial for Lutherans’s Supernus Pharmaceuticals SUPN Stock Holding History

Thrivent Financial for Lutherans’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.98M Sell
38,272
-1,128
-3% -$57.4K ﹤0.01% 1465
2025
Q4 		$1.96M Sell
39,400
-1,593
-4% -$77.5K ﹤0.01% 1505
2025
Q3 		$1.96M Sell
40,993
-177
-0.4% -$7.13K ﹤0.01% 1360
2025
Q2 		$1.3M Buy
41,170
+611
+2% +$19.6K ﹤0.01% 1631
2025
Q1 		$1.33M Sell
40,559
-2,123
-5% -$75.2K ﹤0.01% 1522
2024
Q4 		$1.54M Sell
42,682
-591
-1% -$20.8K ﹤0.01% 1625
2024
Q3 		$1.35M Sell
43,273
-2,363
-5% -$73.7K ﹤0.01% 1719
2024
Q2 		$1.22M Sell
45,636
-1,759
-4% -$51K ﹤0.01% 1738
2024
Q1 		$1.62M Sell
47,395
-1,287
-3% -$38.3K ﹤0.01% 1577
2023
Q4 		$1.41M Sell
48,682
-1,260
-3% -$33.4K ﹤0.01% 1628
2023
Q3 		$1.38M Sell
49,942
-2,171
-4% -$66.1K ﹤0.01% 1551
2023
Q2 		$1.57M Sell
52,113
-1,459
-3% -$51.1K ﹤0.01% 1504
2023
Q1 		$1.94M Sell
53,572
-1,878
-3% -$72.2K ﹤0.01% 1315
2022
Q4 		$1.98M Buy
55,450
+151
+0.3% +$5.25K 0.01% 1268
2022
Q3 		$1.87M Buy
55,299
+2,824
+5% +$91.9K 0.01% 1255
2022
Q2 		$1.52M Buy
52,475
+9,182
+21% +$263K ﹤0.01% 1415
2022
Q1 		$1.4M Buy
43,293
+14
+0% +$429 ﹤0.01% 1580
2021
Q4 		$1.26M Buy
43,279
+321
+0.7% +$9.74K ﹤0.01% 1704
2021
Q3 		$1.15M Sell
42,958
-385
-0.9% -$10.3K ﹤0.01% 1731
2021
Q2 		$1.33M Sell
43,343
-131
-0.3% -$4.02K ﹤0.01% 1663
2021
Q1 		$1.14M Sell
43,474
-135
-0.3% -$3.78K ﹤0.01% 1783
2020
Q4 		$1.1M Sell
43,609
-59
-0.1% -$1.27K ﹤0.01% 1691
2020
Q3 		$910K Sell
43,668
-301
-0.7% -$6.83K ﹤0.01% 1623
2020
Q2 		$1.04M Hold
43,969
– – ﹤0.01% 1468
2020
Q1 		$791K Buy
43,969
+2,195
+5% +$46.1K ﹤0.01% 1442
2019
Q4 		$991K Buy
41,774
+100
+0.2% +$2.43K ﹤0.01% 1499
2019
Q3 		$1.15M Buy
41,674
+628
+2% +$18.6K ﹤0.01% 1319
2019
Q2 		$1.36M Buy
41,046
+1,108
+3% +$38K ﹤0.01% 1208
2019
Q1 		$1.4M Buy
39,938
+2,854
+8% +$106K ﹤0.01% 1151
2018
Q4 		$1.23M Buy
37,084
+815
+2% +$35K ﹤0.01% 1044
2018
Q3 		$1.83M Buy
36,269
+737
+2% +$36.4K 0.01% 938
2018
Q2 		$2.13M Buy
35,532
+860
+2% +$44.6K 0.01% 885
2018
Q1 		$1.59M Buy
34,672
+2,967
+9% +$124K 0.01% 1003
2017
Q4 		$1.26M Buy
31,705
+625
+2% +$24.7K ﹤0.01% 1121
2017
Q3 		$1.24M Buy
31,080
+740
+2% +$32K ﹤0.01% 1059
2017
Q2 		$1.31M Buy
30,340
+2,210
+8% +$78.7K 0.01% 993
2017
Q1 		$880K Buy
28,130
+1,850
+7% +$49.6K ﹤0.01% 1248
2016
Q4 		$664K Buy
26,280
+890
+4% +$19.9K ﹤0.01% 1367
2016
Q3 		$628K Buy
25,390
+8,230
+48% +$186K ﹤0.01% 1351
2016
Q2 		$350K Buy
17,160
+1,890
+12% +$33.5K ﹤0.01% 1588
2016
Q1 		$233K Buy
15,270
+450
+3% +$5.87K ﹤0.01% 1711
2015
Q4 		$199K Buy
+14,820
New +$229K ﹤0.01% 1755

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Thrivent Financial for Lutherans's SUPN Position: Q1 2026 in Review

Thrivent Financial for Lutherans reduced its Supernus Pharmaceuticals (SUPN) stake by 2.9% in Q1 2026, selling an estimated $57.4K and leaving 38,272 shares worth $1.98M. The position accounts for ﹤0.01% of the portfolio, ranked #1465.

Thrivent Financial for Lutherans first reported a position in SUPN in Q4 2015 and has held it in 42 quarters since. The position peaked at $2.13M in Q2 2018. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Thrivent Financial for Lutherans held 38,272 shares of Supernus Pharmaceuticals worth $1.98M as of Q1 2026.
  • Thrivent Financial for Lutherans sold 1,128 Supernus Pharmaceuticals shares in Q1 2026, an estimated $57.4K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q1 2026, its #1465 holding.
  • Thrivent Financial for Lutherans first reported a position in Supernus Pharmaceuticals in Q4 2015 and has held it in 42 quarters since.
  • Thrivent Financial for Lutherans's Supernus Pharmaceuticals position peaked at $2.13M in Q2 2018.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2026, filed 1 May 2026.